Key result
A fixed-dose combination of 20 mg enalapril and 10 mg lercanidipine reduced office blood pressure by 29.2/14.2 mmHg from baseline over 3 months.
Why the study?
Does a fixed-dose combination of enalapril 20 mg and lercanidipine 10 mg reduce blood pressure and improve vascular surrogate endpoints in daily practice?
Observational (n=622)
Open-label
Yes
Does a fixed-dose combination of enalapril 20 mg and lercanidipine 10 mg reduce blood pressure and improve vascular surrogate endpoints in daily practice?
Mean Difference: -29.2
A fixed-dose combination of enalapril 20 mg and lercanidipine 10 mg effectively reduces blood pressure, pulse pressure, and microalbuminuria in daily clinical practice, confirming findings from randomized trials.
Supports real-world BP reduction with this combination; extends randomized trial data but should not yet change practice.
BACKGROUND: A fixed-dose combination (FDC) of enalapril and lercanidipine has been shown to be effective and safe in reducing blood pressure in randomized clinical trials. This study aims to determine effectiveness and safety in daily practice. METHODS: This was a prospective, open-label, uncontrolled multicenter study, with a 3-month follow-up at general practitioners and internists. Patients were treated with an FDC of 20 mg enalapril maleate and 10 mg lercanidipine hydrochloride, and blood pressure was determined in the office (OBPM) and by discretionary self- (SBPM) and ambulatory- (ABPM) measurements. RESULTS: Out of 622 patients (mean age 61.3 ± 13.3 years, 54.2% male): blood pressure was reduced by -29.2/-14.2 mmHg (OBPM) from baseline (164.4/95.2 mmHg). Pulse pressure was reduced by -15.0 ± 16.4 mmHg. Prevalence of microalbuminuria was reduced from 14.6% at baseline to 6.5% (p < 0.001). SBPM data were available for 71% of patients and ABPM for 12%. In the latter patients, blood pressure variability index was significantly reduced compared with baseline over 24 h (14.2 ± 4.2 vs 16.3 ± 4.0; p < 0.001) and with nighttime ABPM (13.7 ± 4.9 vs 15.2 ± 4.4; p = 0.022). Treatment was associated with a low incidence of adverse events (3.4%). CONCLUSIONS: The FDC of 20 mg enalapril-maleate and 10 mg lercanidipine-hydrochloride seems to be effective and well tolerated in clinical practice. It improved vascular surrogate end points, including pulse pressure, blood pressure variability and microalbuminuria.
No takes yet. Share an insight, caveat, or question.
Scholze et al. (2011) conducted an observational in Hypertension (n=622). Fixed-dose combination of enalapril and lercanidipine was evaluated on Office blood pressure (OBPM) reduction from baseline (-29.2/-14.2 mmHg). A fixed-dose combination of 20 mg enalapril and 10 mg lercanidipine reduced office blood pressure by 29.2/14.2 mmHg from baseline over 3 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: